NO2638031T3 - - Google Patents
Info
- Publication number
- NO2638031T3 NO2638031T3 NO11782588A NO11782588A NO2638031T3 NO 2638031 T3 NO2638031 T3 NO 2638031T3 NO 11782588 A NO11782588 A NO 11782588A NO 11782588 A NO11782588 A NO 11782588A NO 2638031 T3 NO2638031 T3 NO 2638031T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41227310P | 2010-11-10 | 2010-11-10 | |
US201161546613P | 2011-10-13 | 2011-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2638031T3 true NO2638031T3 (ru) | 2018-03-10 |
Family
ID=44983512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO11782588A NO2638031T3 (ru) | 2010-11-10 | 2011-11-09 |
Country Status (28)
Country | Link |
---|---|
US (1) | US8815882B2 (ru) |
EP (3) | EP2638031B9 (ru) |
JP (3) | JP5986094B2 (ru) |
KR (1) | KR101566091B1 (ru) |
CN (1) | CN103313978B (ru) |
AR (1) | AR083813A1 (ru) |
AU (1) | AU2011328139A1 (ru) |
BR (1) | BR112013011600B1 (ru) |
CA (2) | CA2812669C (ru) |
CY (1) | CY1120073T1 (ru) |
DK (2) | DK3124483T3 (ru) |
EC (1) | ECSP13012611A (ru) |
ES (2) | ES2653967T3 (ru) |
HK (1) | HK1187605A1 (ru) |
HR (2) | HRP20172006T1 (ru) |
HU (2) | HUE046617T2 (ru) |
IL (1) | IL225234A0 (ru) |
LT (2) | LT2638031T (ru) |
MA (1) | MA34644B1 (ru) |
MX (1) | MX2013005199A (ru) |
NO (1) | NO2638031T3 (ru) |
PL (2) | PL2638031T3 (ru) |
PT (2) | PT2638031T (ru) |
RS (2) | RS56583B1 (ru) |
SG (1) | SG189043A1 (ru) |
SI (2) | SI3124483T1 (ru) |
TW (1) | TW201302733A (ru) |
WO (1) | WO2012062783A1 (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2837199A1 (en) | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Cinnoline compounds as inhibitor of lrrk2 kinase activity |
US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
WO2013079493A1 (en) | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
PL2785711T3 (pl) * | 2011-11-29 | 2017-01-31 | F.Hoffmann-La Roche Ag | Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona |
CN103958498B (zh) * | 2011-11-29 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
CA2871375C (en) * | 2012-05-03 | 2020-10-27 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
KR102091894B1 (ko) * | 2012-05-03 | 2020-03-20 | 제넨테크, 인크. | Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
WO2014001973A1 (en) | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
CA2933927C (en) | 2013-12-17 | 2021-11-16 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
JP6483707B2 (ja) | 2013-12-20 | 2019-03-13 | シグナル ファーマシューティカルズ,エルエルシー | 置換されたジアミノピリミジル化合物、それらの組成物、及びそれらによる治療方法 |
SG11201605342UA (en) * | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
US9394281B2 (en) * | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
AU2015201630A1 (en) * | 2014-03-31 | 2015-10-15 | Commonwealth Scientific And Industrial Research Organisation | Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices |
GB2538476B (en) * | 2014-05-08 | 2019-03-20 | Tosoh F Tech Inc | 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same |
US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
JP6262079B2 (ja) * | 2014-06-02 | 2018-01-17 | 東ソー・ファインケム株式会社 | 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法 |
JP6431294B2 (ja) * | 2014-06-16 | 2018-11-28 | 東ソー・ファインケム株式会社 | 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法 |
JP6649540B2 (ja) | 2014-10-14 | 2020-02-19 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換されたヘテロアリール化合物および使用方法 |
EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
AU2017242225B2 (en) | 2016-03-29 | 2021-02-18 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
US10428024B2 (en) | 2016-04-28 | 2019-10-01 | Merck Patent Gmbh | Piperidinyl derivatives |
CA3025672A1 (en) | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
WO2018155947A1 (ko) | 2017-02-24 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
US20200157081A1 (en) * | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
AR112392A1 (es) * | 2017-07-14 | 2019-10-23 | Glaxosmithkline Ip Dev Ltd | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
UA126414C2 (uk) | 2017-11-21 | 2022-09-28 | Деналі Терапьютикс Інк. | Поліморфи та тверді форми піримідиніламінопіразолової сполуки та способи їх отримання |
JP7284172B2 (ja) * | 2017-12-20 | 2023-05-30 | デナリ セラピューティクス インコーポレイテッド | ピリミジニル-4-アミノピラゾール化合物の調製方法 |
JP7364841B2 (ja) * | 2018-02-14 | 2023-10-19 | 智彦 大和田 | 酸ハロゲン化物による化合物の製造方法 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
AU2020282348A1 (en) * | 2019-05-31 | 2021-12-02 | Denali Therapeutics Inc. | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment |
CN110627810A (zh) * | 2019-06-05 | 2019-12-31 | 中国医学科学院药用植物研究所 | 一种三氟甲基吡唑衍生物的制备方法 |
WO2021178485A1 (en) * | 2020-03-06 | 2021-09-10 | National Health Research Institutes | Pyrimidine compounds and their pharmaceutical uses |
EP4129994A1 (en) | 2020-03-23 | 2023-02-08 | Whan In Pharmaceutical Co., Ltd. | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
KR20230091871A (ko) | 2020-10-20 | 2023-06-23 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법 |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4308115A1 (en) * | 2021-03-17 | 2024-01-24 | Merck Sharp & Dohme LLC | Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
IL307165A (en) * | 2021-03-26 | 2023-11-01 | Sumitomo Pharma Oncology Inc | ALK-5 inhibitors and their uses |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
WO2023224894A1 (en) * | 2022-05-20 | 2023-11-23 | Merck Sharp & Dohme Llc | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体 |
AU692484B2 (en) | 1993-10-12 | 1998-06-11 | Du Pont Pharmaceuticals Company | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof |
ES2361146T3 (es) | 1998-03-27 | 2011-06-14 | Janssen Pharmaceutica Nv | Derivados de la piramidina inhibitatoria de vih. |
US6458823B1 (en) | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
US6172222B1 (en) | 1998-06-08 | 2001-01-09 | American Home Products Corporation | Diaminopyrazoles |
AP1683A (en) | 1998-11-10 | 2006-11-29 | Janssen Pharmaceutica Nv | HIV replication inhibiting pyrimidines. |
PL366110A1 (en) | 1999-08-13 | 2005-01-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
EE04991B1 (et) | 1999-09-24 | 2008-04-15 | Janssen Pharmaceutica N.V. | Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
CA2406562C (en) | 2000-05-08 | 2009-09-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422380C (en) | 2000-09-15 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4377583B2 (ja) | 2000-12-05 | 2009-12-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | C−junn末端キナーゼ(jnk)および他のタンパク質キナーゼのインヒビター |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
CN100340555C (zh) | 2000-12-21 | 2007-10-03 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
IL156306A0 (en) | 2000-12-21 | 2004-01-04 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
WO2003000186A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
ES2314106T3 (es) | 2001-10-17 | 2009-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion. |
WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003212282A1 (en) * | 2002-03-11 | 2003-09-22 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
BR0316680A (pt) | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
JP2006515014A (ja) | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体 |
EP1628962B1 (de) | 2003-05-21 | 2014-10-01 | Bayer Intellectual Property GmbH | Iodpyrazolylcarboxanilide |
WO2005009977A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
WO2005012298A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
CN1849318B (zh) * | 2003-07-30 | 2011-10-12 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法 |
ES2365223T3 (es) | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
EP1765791A1 (en) | 2004-07-08 | 2007-03-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
EP1786783A1 (en) | 2004-09-01 | 2007-05-23 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
AU2005315392B2 (en) | 2004-12-17 | 2010-03-11 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors |
JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
DE102005008310A1 (de) | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
JP2008540391A (ja) * | 2005-05-05 | 2008-11-20 | アストラゼネカ アクチボラグ | ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用 |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
EP1890703B1 (en) | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
WO2007030362A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono Sa. | Ikk inhibitors for the treatment of endometriosis |
EP1934200A1 (en) * | 2005-09-15 | 2008-06-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
US8623887B2 (en) | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
EP2032543A1 (en) | 2006-06-15 | 2009-03-11 | Boehringer Ingelheim International GmbH | 2-anilino-4-aminoalkyleneaminopyrimidines |
US20080131937A1 (en) | 2006-06-22 | 2008-06-05 | Applera Corporation | Conversion of Target Specific Amplification to Universal Sequencing |
EP2059512A1 (en) | 2006-08-01 | 2009-05-20 | Praecis Pharmaceuticals Incorporated | P38 kinase inhibitors |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
US20080194575A1 (en) | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
CA2669128C (en) | 2006-11-27 | 2011-07-12 | Ares Trading S.A. | Treatment for multiple myeloma |
BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
CN101563327A (zh) | 2006-12-19 | 2009-10-21 | 健泰科生物技术公司 | 嘧啶类激酶抑制剂 |
EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
US20100144706A1 (en) | 2006-12-22 | 2010-06-10 | Boehringer Ingelheim International Gmbh | Compounds |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
UY31048A1 (es) | 2007-04-25 | 2008-11-28 | Astrazeneca Ab | Nuevos compuestos de pirimidina y usos de los mismos |
EP2164841A1 (en) | 2007-06-08 | 2010-03-24 | Bayer CropScience SA | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
KR20100049068A (ko) | 2007-07-17 | 2010-05-11 | 리겔 파마슈티칼스, 인크. | Pkc 억제제로서의 시클릭 아민 치환된 피리미딘디아민 |
ES2457394T3 (es) | 2007-09-28 | 2014-04-25 | Cyclacel Limited | Derivados de pirimidina como inhibidores de proteína cinasa |
JP5548130B2 (ja) | 2007-10-09 | 2014-07-16 | ダウ アグロサイエンシィズ エルエルシー | 殺虫性ピリミジニルアリールヒドラゾン |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
CA2707653A1 (en) | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
PT2231636E (pt) | 2007-12-07 | 2012-01-02 | Novartis Ag | Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina |
PL2265607T3 (pl) | 2008-02-15 | 2017-07-31 | Rigel Pharmaceuticals, Inc. | Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK |
CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
ES2645689T3 (es) | 2008-05-21 | 2017-12-07 | Ariad Pharmaceuticals, Inc. | Derivados de fósforo como inhibidores de quinasas |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患を治療するための2−ヘテロシクリルアミノアルキル−(p−キノン)誘導体 |
PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TW201018681A (en) | 2008-07-31 | 2010-05-16 | Genentech Inc | Pyrimidine compounds, compositions and methods of use |
WO2010024430A1 (ja) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-ジアミノピリミジン化合物 |
JP2012501983A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 4−アルキル−置換ジアミノピリミジン類 |
BRPI0918091A2 (pt) | 2008-09-03 | 2015-08-11 | Bayer Cropscience Ag | Anilinopirimidinas heterociclicamente substituídas como fungicidas |
EA201100434A1 (ru) | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | Гетероциклически замещенные анилинопиримидины в качестве фунгицидов |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010080712A2 (en) | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
BRPI1013493A2 (pt) * | 2009-03-30 | 2016-04-05 | Astellas Pharma Inc | composto de pirimidina |
WO2010118986A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
CA2763717A1 (en) | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
CA2764983A1 (en) | 2009-06-10 | 2010-12-16 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
WO2010146133A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
WO2010146132A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
IN2012DN02534A (ru) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
SG179120A1 (en) | 2009-09-29 | 2012-05-30 | Glaxo Group Ltd | Novel compounds |
KR101663637B1 (ko) | 2009-11-13 | 2016-10-07 | 제노스코 | 키나아제 억제제 |
AU2010343056A1 (en) | 2009-12-29 | 2012-08-02 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
PT2576541T (pt) * | 2010-06-04 | 2016-07-08 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
WO2013079493A1 (en) * | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
CN103958498B (zh) * | 2011-11-29 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
PL2785711T3 (pl) * | 2011-11-29 | 2017-01-31 | F.Hoffmann-La Roche Ag | Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona |
WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
-
2011
- 2011-11-09 KR KR1020137014605A patent/KR101566091B1/ko active IP Right Grant
- 2011-11-09 DK DK16180927.2T patent/DK3124483T3/da active
- 2011-11-09 ES ES11782588.5T patent/ES2653967T3/es active Active
- 2011-11-09 LT LTEP11782588.5T patent/LT2638031T/lt unknown
- 2011-11-09 EP EP11782588.5A patent/EP2638031B9/en active Active
- 2011-11-09 HU HUE16180927A patent/HUE046617T2/hu unknown
- 2011-11-09 US US13/292,668 patent/US8815882B2/en active Active
- 2011-11-09 SG SG2013021100A patent/SG189043A1/en unknown
- 2011-11-09 NO NO11782588A patent/NO2638031T3/no unknown
- 2011-11-09 PL PL11782588T patent/PL2638031T3/pl unknown
- 2011-11-09 LT LTEP16180927.2T patent/LT3124483T/lt unknown
- 2011-11-09 CA CA2812669A patent/CA2812669C/en active Active
- 2011-11-09 BR BR112013011600-5A patent/BR112013011600B1/pt active IP Right Grant
- 2011-11-09 RS RS20171211A patent/RS56583B1/sr unknown
- 2011-11-09 PT PT117825885T patent/PT2638031T/pt unknown
- 2011-11-09 EP EP19184916.5A patent/EP3590933B1/en active Active
- 2011-11-09 RS RS20191033A patent/RS59106B1/sr unknown
- 2011-11-09 CN CN201180053793.8A patent/CN103313978B/zh active Active
- 2011-11-09 DK DK11782588.5T patent/DK2638031T3/en active
- 2011-11-09 AR ARP110104181A patent/AR083813A1/es not_active Application Discontinuation
- 2011-11-09 JP JP2013538172A patent/JP5986094B2/ja active Active
- 2011-11-09 MX MX2013005199A patent/MX2013005199A/es active IP Right Grant
- 2011-11-09 HU HUE11782588A patent/HUE037844T2/hu unknown
- 2011-11-09 EP EP16180927.2A patent/EP3124483B1/en active Active
- 2011-11-09 WO PCT/EP2011/069696 patent/WO2012062783A1/en active Application Filing
- 2011-11-09 AU AU2011328139A patent/AU2011328139A1/en not_active Abandoned
- 2011-11-09 PT PT161809272T patent/PT3124483T/pt unknown
- 2011-11-09 CA CA3017869A patent/CA3017869C/en active Active
- 2011-11-09 ES ES16180927T patent/ES2746134T3/es active Active
- 2011-11-09 PL PL16180927T patent/PL3124483T3/pl unknown
- 2011-11-09 TW TW100140970A patent/TW201302733A/zh unknown
- 2011-11-09 SI SI201131772T patent/SI3124483T1/sl unknown
- 2011-11-09 SI SI201131377T patent/SI2638031T1/en unknown
-
2013
- 2013-03-14 IL IL225234A patent/IL225234A0/en unknown
- 2013-05-03 MA MA35869A patent/MA34644B1/fr unknown
- 2013-05-08 EC ECSP13012611 patent/ECSP13012611A/es unknown
-
2014
- 2014-01-16 HK HK14100468.7A patent/HK1187605A1/xx unknown
-
2016
- 2016-08-04 JP JP2016153608A patent/JP6298115B2/ja active Active
-
2017
- 2017-12-27 CY CY20171101349T patent/CY1120073T1/el unknown
- 2017-12-29 HR HRP20172006TT patent/HRP20172006T1/hr unknown
-
2018
- 2018-02-22 JP JP2018029462A patent/JP6524284B2/ja active Active
-
2019
- 2019-10-02 HR HRP20191781TT patent/HRP20191781T1/hr unknown